Key result
Letter highlights PAR-1 IgG autoantibodies in COVID-19 without reporting primary clinical data.
Answers are grounded in this paper and cite their sources.
Does not alter practice; leaves open whether PAR-1 IgG autoantibodies contribute to COVID-19 thrombosis.
Publication History Received: 15 October 2024 Accepted: 16 October 2024 Accepted Manuscript online: 17 October 2024 Article published online: 07 November 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany Letter to this article: Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19 Thromb Haemost 2024; 124(12): 1164-1166 DOI: 10.1055/a-2205-0014
No takes yet. Share an insight, caveat, or question.
Kendrick et al. (2024) conducted a letter in COVID-19. PAR1 Autoantibodies was evaluated. This publication is a letter or editorial regarding protease-activated receptor-1 IgG autoantibodies in patients with COVID-19, with no primary clinical data reported in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: